Factors associated with grade II-IV acute GVHD: multiple regression analysis
| Factor . | RR of acute GVHD (95% CI) . | P . |
|---|---|---|
| Number of donors | ||
| One* | 1.0 | |
| Two | 2.0 (1.2-3.4) | .01 |
| Conditioning | ||
| Myeloablative* | 1.0 | |
| Nonmyeloablative | 1.7 (1.1-2.5) | .01 |
| ATG in conditioning | ||
| No* | 1.0 | |
| Yes | 0.5 (0.3-0.9) | .02 |
| MMF as GVHD prophylaxis | ||
| No* | 1.0 | |
| Yes | 0.5 (0.2-1.3) | .14 |
| HLA matching (engrafting unit) | ||
| 6/6* | 1.0 | |
| 5/6 | 1.9 (0.9-4.2) | .11 |
| 4/6 | 1.4 (0.7-3.2) | .36 |
| Disease risk | ||
| Standard* | 1.0 | |
| High | 0.7 (0.5-1.1) | .10 |
| Factor . | RR of acute GVHD (95% CI) . | P . |
|---|---|---|
| Number of donors | ||
| One* | 1.0 | |
| Two | 2.0 (1.2-3.4) | .01 |
| Conditioning | ||
| Myeloablative* | 1.0 | |
| Nonmyeloablative | 1.7 (1.1-2.5) | .01 |
| ATG in conditioning | ||
| No* | 1.0 | |
| Yes | 0.5 (0.3-0.9) | .02 |
| MMF as GVHD prophylaxis | ||
| No* | 1.0 | |
| Yes | 0.5 (0.2-1.3) | .14 |
| HLA matching (engrafting unit) | ||
| 6/6* | 1.0 | |
| 5/6 | 1.9 (0.9-4.2) | .11 |
| 4/6 | 1.4 (0.7-3.2) | .36 |
| Disease risk | ||
| Standard* | 1.0 | |
| High | 0.7 (0.5-1.1) | .10 |
Reference group.